ClinicalTrials.gg
RecruitingNCT00001184Updated Oct 26, 2026

Immune Regulation in Ulcerative Colitis or Crohn s Disease

An observational study in Inflammatory Bowel Disease, Ulcerative Colitis and Chrohn's Disease, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Recruiting at 1 site in United States. Open to participants aged 1 Day to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.

Primary conditionColitis, UlcerativeRegistry: Inflammatory Bowel DiseasesReclassifiedWhy we changed it
Registry
Inflammatory Bowel Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Colitis, Ulcerative
Why
  1. The study's listed conditions name Colitis, Ulcerative, a narrower term within Inflammatory Bowel Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Observational

From the registry’s dates

  • Started Aug 1998; still recruiting 28 years 3 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
1 Day to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 615 studies in Colitis, Ulcerative with a site in United States — 116 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.

Planned enrollment
23rd of 113
1,000 · median 198
Started
1998
the only one that year
Observational
113 of 615
30 open now
Registered
1st of 615
by date

Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 23rd largest by planned enrollment of the 113 observational ones that give a count, is the only one that started in 1998, is one of 113 observational ones, and was the 1st registered.

Colitis, Ulcerative

1,853 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

116 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:

111 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 71 take children under 18; 40 take healthy volunteers.

This study: 1 Day to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 615 studies in Colitis, Ulcerative with a site in United States, or all of them as a file.
02

Study summary

This study will investigate in patients with Crohn s disease and ulcerative colitis how the body s immune system controls inflammation in the gastrointestinal tract (stomach and intestines)-specifically, how lymphocytes (a type of white blood cell) function in inflammatory responses. This protocol does not involve any experimental treatments.

Patients between the ages of 0 and 75 years of age with Crohn s disease or ulcerative colitis or symptoms of inflammatory bowel disease may be eligible for this study. Screening tests may include the following: medical history and physical examination, routine blood tests, examination of stool specimens, X-rays such as barium enema or upper GI series, proctosigmoidoscopy, colonoscopy, gastroduodenoscopy, and small bowel biopsy.

Participants will receive medical treatment according to the best generally accepted measures for treating Crohn s disease or ulcerative colitis. This may include anti-inflammatory drugs, immunosuppressive drugs, and antibiotics to treat infections. A surgical consultation may be recommended for patients whose disease does not respond to medical treatment. If surgery to remove intestinal tissue is recommended, a qualified gastrointestinal surgeon will perform the procedure.

In addition, participants may undergo the following procedures:

  • Blood drawing - No more than 450 milliliters (30 tablespoons, or 15 ounces) of blood will be taken from adults over a 6-week period. A maximum of 7 ml (1/2 tablespoon) of blood per kilogram (2.2. pounds) of body weight will be obtained from children within the same time period, with no more than 3 ml/kg taken at any one time.
  • Leukapheresis - This procedure is done to collect large quantities of white blood cells. Whole blood is collected through a needle in an arm vein, similar to donating blood. The blood is circulated through a machine that separates it into its components, and the white cells are removed. The rest of the blood is returned to the body, either through the same needle or through another needle in the other arm.
  • Intestinal biopsies - Intestinal tissue will be obtained during colonoscopy with intestinal biopsy in patients who require this procedure as part of their standard medical care. Patients are given a sedative to reduce anxiety, but are conscious during the procedure. A flexible tube is inserted into the rectum and large intestine, allowing the physician to see the intestinal mucosa. At various places, small pieces of tissue are plucked out.
Read the detailed description

STUDY DESCRIPTION:

This natural history protocol provides for the evaluation of patients with idiopathic inflammatory bowel diseases (ulcerative colitis, Crohn s disease, IBD associated with immunodeficiency and genetic diseases such as chronic granulomatous disease, and additional undefined inflammatory conditions of the gut) either on an inpatient or outpatient basis.

OBJECTIVES:

Primary Objective: To identify the molecular abnormalities that result in inflammatory bowel diseases and develop novel therapies based on these discoveries.

Secondary Objectives: To enroll patients with IBD in order to obtain clinical, therapeutic, immunological, and genetic data relevant to the research study of their disease.

ENDPOINTS:

Primary Endpoint: Comparison of the molecular and cellular abnormalities that result in inflammatory bowel diseases

03

Conditions studied

  • Inflammatory Bowel Disease
  • Ulcerative Colitis
  • Chrohn's Disease

Browse trials for

Keywords

  • CGD related IBD
  • IBD Hermansky-Pudlak Syndrom
  • Natural History
04

In context

Colitis, Ulcerative Reclassified

1,853 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 198 across 551 observational studies indexed under Colitis, Ulcerative.

Browse Colitis, Ulcerative studies →

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,446 studies on the registry; 179 are open to participants now.

Of its 405 completed or terminated interventional studies of FDA-regulated products, 302 (75%) have results posted.

Compared within Colitis, Ulcerative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammatory Bowel Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
1 Day to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Clinical

Eligibility criteria

  • INCLUSION CRITERIA:

    1. Patients with a verifiable diagnosis of Crohn s disease, ulcerative colitis, or IBD known to be associated with a co-existing condition and which is supported by characteristic clinical features, radiographic or endoscopic findings, or consistent histopathologic mucosal

      changes OR

    2. Patients with clinical features consistent with an unclassified inflammatory bowel disease and histologic evidence of inflammation of the intestine OR
    3. Patients with any clinical features consistent with inflammatory bowel disease (intestinal inflammation), including but not limited to abdominal pain, fistulae, weight loss, diarrhea, hematochezia or melena or suggestive extra-intestinal symptoms (pyoderma, erythema

      nodosum, axial and articular arthralgias, uveitis, fatigue, fever), in which a diagnosis has not been verified. OR

    4. Patients who have a defined genetic syndrome linked to inflammatory bowel disease risk with or without symptoms or findings consistent with IBD
    5. All subjects to be enrolled will be between ages 0-75 (Participants coming to the NIH Clinical Center must meet age and weight requirements of the clinical center, but > 18 must years old for patients without IBD and may be as young as 0-2 years old for mail-in

      samples).

    6. To participate in the research during endoscopy, subjects must have the following lab values within two weeks of the procedure:

      • Hematocrit > 30%
      • count > 100,000
      • PT \< 1.3 or PTT prolonged by \< 3 seconds
    7. Ability to consent to the protocol on their own.

INCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:

  1. Must be willing to undergo blood draw and/or upper endoscopy and colonoscopy with biopsy to obtain material for research purposes.
  2. Must be >=18 years old.
  3. Must be willing to submit samples for storage.

INCLUSION OF EMPLOYEES IN THE NIH INTRAMURAL STUDIES:

NIH employees and members of their immediate families may participate in this protocol. We will follow the Guidelines for the Inclusion of Employees in NIH Research Studies and will give each employee a copy of the NIH information sheet on Employee Research Participation.

For NIH employees:

  1. Neither participation nor refusal to participate will have an effect, either beneficial or adverse, on the participant s employment or work situation.
  2. The NIH information sheet regarding NIH employee research participation will be distributed to all potential subjects who are NIH employees.
  3. The employee subject s privacy and confidentiality will be preserved in accordance with NIH Clinical Center and NIAID policies, which define the scope and limitations of the protections.
  4. For NIH employee subjects, consent will be obtained by an individual independent of the employee s team. Those in a supervisory position to any employee and co-workers of the employee will not obtain consent. The protocol study staff will be trained annually on obtaining potentially sensitive and private information from co-workers or subordinates. This training will be reinforced as needed, at weekly team meetings.

EXCLUSION CRITERIA:

  1. Failure to meet the inclusion criteria.
  2. Any medical, psychiatric, or social conditions which, in the opinion of the investigators, would make participation in this protocol not in the best interest of the subject.

EXCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:

  1. History of inflammatory bowel disease.
  2. Acute systemic or intestinal infection requiring antibiotics
  3. Any condition that, in the investigator s opinion, places the patient at undue risk by participating in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)

Groups and cohorts

  • 1

    Patients between the ages of 0 and 75 years of age with Crohn s disease or ulcerative colitis or symptoms of inflammatory bowel disease may be eligible for this study.

07

What researchers measure

Primary outcomes

  1. To identify the molecular abnormalities that result in inflammatory bowel diseases and develop novel therapies based on these discoveries.

    observational

    Time frame: at close of study

08

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
09

References and documents

10

Timeline

3 registry updates since Sep 25, 2026

Started Aug 1998 (actual).

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 1999
First posted
Nov 4, 1999
StartActual
Aug 7, 1998
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
3 updates, last Oct 15, 2026
Show all 3 updates
  1. Oct 15, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 9, 2026
    Minor edits only
    + 1 other change: verification date
  3. Oct 5, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT00001184
Responsible party
Sponsor
First posted
Nov 4, 1999
Start date
Aug 7, 1998
Last update
Oct 26, 2026

Study contacts

Sandra M Maxwell, R.N.
Contact
maxwells@mail.nih.gov
(240) 627-3078
Ivan J Fuss, M.D.
Contact
ifuss@niaid.nih.gov
(301) 761-7091
Ivan J Fuss, M.D.
principal investigator · National Institute of Allergy and Infectious Diseases (NIAID)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion